ICMR Licenses Indigenous Malaria Vaccine AdFalciVax to Five Companies

The Indian Council of Medical Research (ICMR) has licensed its pioneering multi-stage malaria vaccine AdFalciVax to five pharmaceutical companies, marking a significant step forward in India’s fight against the disease.

The beneficiaries of the licenses are Indian Immunologicals Limited, Techinvention Lifecare Private Limited, Panacea Biotec Limited, Biological E Limited, and Zydus Lifesciences, officials announced at the India MedTech Expo 2025 held recently in New Delhi.

Developed by the Regional Medical Research Centre (RMRC), Bhubaneswar, under ICMR, AdFalciVax is India’s first indigenous recombinant malaria vaccine. It has been designed to prevent Plasmodium falciparum infection—one of the deadliest malaria parasites—and reduce its community transmission.

The move is expected to accelerate large-scale production and distribution of the vaccine, bolstering public health efforts against malaria in India and potentially other affected regions.